Novel technology further establishes Mursla’s capabilities to uniquely analyse exosome biology for clinical translation

Access to Roche Diagnostics’ expertise in the UK secured in recognition of Mursla’s differentiated value proposition for liquid biopsy

New logo symbolises the secretion of an exosome from its parental cell along with its markers of origin.

Key opinion leaders in the fields of exosomes, liquid biopsy and liver disease support Mursla’s ambition

Mursla has been granted two patents for its novel nanoelectronics-based sensitive detection method for exosomes.

Mursla is dedicating resources to help improve COVID-19 diagnostics & therapeutics solutions. We are currently capitalising upon our...

Mursla was selected again as one of the most exciting tech companies to follow in the Cambridge cluster. https://www.cambridgeindependent...

We are delighted to have won the #onetowatch award as one of the most innovative companies in Cambridgeshire and East of England. The...